Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX supplies the missing protein needed for the intrinsic coagulation cascade. By converting factor X to Xa, it enables the generation of thrombin and the formation of a stable fibrin clot, thereby achieving hemostasis.

The dose of Immunine is individualized. The prescribing clinician determines the amount and frequency based on the patient’s factor IX activity level, severity of hemophilia, and clinical situation such as surgery or bleeding episodes.

The safety of Immunine in pregnancy and lactation has not been established. Clinicians must weigh the potential benefits against unknown risks and consider alternative management strategies when possible.

To order Immunine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Immunine is a factor IX replacement product similar to other plasma‑derived or recombinant factor IX concentrates. Compared with bypassing agents, it directly restores the deficient protein, offering targeted correction of the clotting defect, but choice of therapy depends on inhibitor status, patient preference, and clinical guidelines.

Immunine should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the product to maintain stability.

Immunine is administered intravenously. The infusion is performed by a qualified healthcare professional using aseptic technique, with the rate and volume adjusted according to the prescribed dose and patient tolerance.

The most serious risks include the development of inhibitory antibodies against factor IX, severe allergic or anaphylactic reactions, and thromboembolic events. Monitoring for inhibitors and signs of hypersensitivity is essential during therapy.

Immunine is contraindicated in patients with known hypersensitivity to any component of the product. It should also be used with caution in individuals with a history of thromboembolic disease or those who have previously developed inhibitors to factor IX.